Therapeutic profile of orphan medicines

Pharmacoepidemiology and Drug Safety

Volumn 16, Issue 4, 2007, Pages 435-440

  Teixeira de Barros, Carla Maria ^a   Papoila, Ana Luísa ^b  

^a UNIVERSITY OF LISBON   (Portugal)

^b UNIVERSIDADE NOVA DE LISBOA   (Portugal)

Author keywords

Drug utilisation studies; Orphan medicines; Rare diseases; Therapeutic profile

Indexed keywords

ALPHA 1 ANTITRYPSIN; ANAGRELIDE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BOSENTAN; CAFFEINE CITRATE; COMPLEMENT COMPONENT C1S INHIBITOR; DENILEUKIN DIFTITOX; HEPATITIS B ANTIBODY; HYDROXYUREA; ILOPROST; IMATINIB; IMMUNOMODULATING AGENT; NITISINONE; ORPHAN DRUG; PANCREATIN; STIRIPENTOL; THALIDOMIDE; TOBRAMYCIN; TRIENTINE;

ADOLESCENT; ADULT; AGE; AGED; ANGIONEUROTIC EDEMA; ARTICLE; CANCER; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; EVIDENCE BASED PRACTICE; FABRY DISEASE; FEMALE; GASTROINTESTINAL STROMAL TUMOR; HEPATITIS B; HOSPITAL PATIENT; HOSPITAL PHARMACY; HUMAN; INFANT; INFORMATION PROCESSING; LICENCE; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; NEWBORN; NEWBORN APNEA; OFF LABEL DRUG USE; PHARMACEUTICAL CARE; PORTUGAL; PRACTICE GUIDELINE; PREMATURITY; PREVALENCE; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK MANAGEMENT; SEX DIFFERENCE; SICKLE CELL ANEMIA; STATISTICAL SIGNIFICANCE; WILSON DISEASE;

ADOLESCENT; ADULT; AGED; ANTIHYPERTENSIVE AGENTS; ANTINEOPLASTIC AGENTS; CAFFEINE; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; CITRATES; CROSS-SECTIONAL STUDIES; DRUG LABELING; DRUG UTILIZATION; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; ORPHAN DRUG PRODUCTION; PHARMACY SERVICE, HOSPITAL; PORTUGAL; PRESCRIPTIONS, DRUG; RARE DISEASES; SULFONAMIDES;

EID: 34247471785     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1315     Document Type: Article

References (25)

1. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on Orphan Medicinal Products. Official Journal 2018, 22 January 2000; 1-5.
2. Salinas C. Medicamentos huerfanos: consideraciones legales y socials. Cienc Tecnol Pharm 1999; 9(3): 134-142.
3. Campos-Castel1ó J. Medicamentos huerfaros y enfermedades huérfanas. Rev Neurol 2001; 33(3): 216-220.
4. Reider C. The orphan drug act: provisions and considerations. Drug Inf 2000; 34: 295-300.
5. Shiragami M, Nakai K. Development of orphan drugs in Japan: characteristics of orphan drugs developed in Japan. Drug Inf 2000; 34: 839-846.
6. Meyers AS. Orphan drugs: the current situation in the United States, Europe and Asia. Drug Inf J 1997; 31: 101-104.
7. Carson R, Reider MS. The orphan drug act: provisions and considerations. Drug Inf J 2000; 34: 295-300.
8. Lavandeira A. Orphan drugs: legal aspects, current situation. Haemophilia 2002; 8: 194-198.
9. Trouiller P, Olliaro P, Torreele E, et al. Drug development for neglected diseases: a deficient market and public-health policy failure. The Lancet 2002; 359: 2188-2193.
10. Iribarne A. Orphan diseases and adoptive initiatives. JAMA 2003; 90(1): 116.
11. Martinez ME, Fernandez AA. Enfoque interdisciplinario de las enfermedades raras: un nuevo reto para un nuevo siglo. Med Clin (Barc) 2003; 121(8): 299-303.
12. Haffner M. The current environment in orphan drug development. Drug Inf J 2003; 37: 373-379.
13. Carr M, Lilinares-Garcia J. Orphan drugs: new emerging treatments. Hosp Pharm Europe 2005; 21: 65-66.
14. European Agency for the Evaluation of Medicinal Products. Register of designated orphan medicinal products [homepage on the Internet] [cited 2006 Feb 31. Available from http://pharmacos.eudra.org/F2/register/ orphreg.htm.
15. Food and Drug Administration. List of approved orphan medicinal products [homepage on the Internet) [cited 2006 Mar 26]. Available from www.fda.gov/orphan/.
16. Hulton A, Greener M. Increasing the use of orphan drugs in clinical practice. Hosp Med 2004; 65(7): 400-403.
17. Ceci A, Felisi M, Catapano M, et al. Medicines for children licensed by the European Agency for the Evaluation of Medicinal Products. Eur J Clin Pharmacol 2002; 58: 495-500.
18. Badesch D, Abman S, Ahearn G, et al. Medical therapy for pulmonary arterial hypertension. ACCP Evidence-based clinical practice guidelines. Chest 2004; 126: 35S-62S.
19. McCrory D, Lewis S. Methodology and grading for pulmonary hypertension evidence review and guideline development. Chest 2004; 126: 11S-13S.
20. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 30: 1425-1436.
21. Segal ES, Valette C, Oster L, et al. Risk management in the postmarketing period: safety experience with the US and European bosentan surveillance programmes. Drug Saf 2005; 28(11): 971-980.
22. Paurisson F. Survey of diagnostic delays, 8 diseases, Europe [monograph on the Internet] 2005 [cited 2006 Jan 24]. Available from http://www.eurordis.org/imprimer.php3?id_article=454
23. Campos-Castelló J, Ponsot G, Feillet F, Vidailhet M, Maire I, et al. Orphan drugs and orphan diseases. Europ J Paediatr Neurol 2000; 4: 141-149.
24. Martinez MI, Fernandez AA. Enfoque interdisciplinario de las enfermedades raras: un Nuevo reto para un Nuevo siglo. Med Clin (Barc) 2003; 121(8): 299-303.
25. Cordier JF, Aymé S. Les maladies orphelines. La Revue du Praticien 2004; 54: 777-779.